Organon (OGN) Inventory Average (2021 - 2026)
Organon (OGN) recorded quarterly Inventory Average of $1.4 billion in Q1 2026, down 3.97% quarter-over-quarter from $1.4 billion in Q4 2025, and up 3.58% on a YoY basis from $1.3 billion in Q1 2025.
Organon (OGN) Inventory Average (2021 - 2026) Analysis & Trends
Organon's Inventory Average history runs 6 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Inventory Average rose 3.58% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 3.58% YoY), while the FY2025 annual figure was $1.4 billion, up 3.45% from the prior year.
- Inventory Average was $1.4 billion for Q1 2026 at Organon, down from $1.4 billion in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $1.5 billion in Q3 2025 to a low of $914.5 million in Q3 2022.
- Historically, Inventory Average has averaged $1.2 billion across 5 years, with a median of $1.3 billion in 2024.
- The sharpest annual moves came in 2022 and 2023: Inventory Average gained 1.31% in 2022, then soared 32.89% in 2023.
- A 5-year view of Inventory Average shows it stood at $941.0 million in 2022, then jumped by 32.89% to $1.3 billion in 2023, then grew by 8.12% to $1.4 billion in 2024, then advanced by 7.03% to $1.4 billion in 2025, then retreated by 3.97% to $1.4 billion in 2026.
- The last three Inventory Average figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | 8.09 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | 14.14 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 14.39 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | 5.00 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | 2.72 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 1.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Bn |
| Dec 31, 2025 | 1.45 Bn |
| Sep 30, 2025 | 1.47 Bn |
| Jun 30, 2025 | 1.41 Bn |
| Mar 31, 2025 | 1.34 Bn |
| Dec 31, 2024 | 1.35 Bn |
| Sep 30, 2024 | 1.34 Bn |
| Jun 30, 2024 | 1.28 Bn |
| Mar 31, 2024 | 1.29 Bn |
| Dec 31, 2023 | 1.25 Bn |
| Sep 30, 2023 | 1.19 Bn |
| Jun 30, 2023 | 1.16 Bn |
| Mar 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 941.00 Mn |
| Sep 30, 2022 | 914.50 Mn |
| Jun 30, 2022 | 948.00 Mn |
| Mar 31, 2022 | 930.50 Mn |
| Dec 31, 2021 | 916.50 Mn |
| Sep 30, 2021 | 894.50 Mn |
| Jun 30, 2021 | 897.50 Mn |